IP Library Granted Patent US 9,066,875
Granted Patent B2
US 9,066,875 · App. 14/083,187 · Granted Jun 30, 2015

Microfabricated nanopore device for sustained release of therapeutic agent

Inventors: Francis J. Martin (San Francisco, CA); Anthony A. Boiarski (Hilliard, OH)
Assignee: Delpor, Inc.
A61K9/4808A61M5/14276A61K9/1694A61K9/0004A61K9/0024A61K9/0097A61M5/16804A61K38/27A61M31/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,066,875
App. No.
14/083,187
Granted
Jun 30, 2015
Kind
B2
Abstract

A drug delivery device that includes a capsule for implantation into the body; the capsule further includes a reservoir for containing a substance such as a therapeutic agent, at least one port for allowing the substance to diffuse from or otherwise exit the reservoir, and a nanopore membrane in communication with the capsule at or near the exit port for controlling the rate of diffusion of the substance from the exit port. The device also includes an optional screen for providing structural stability to the nanopore membrane and for keeping the pores of the nanopore membrane clear. One embodiment of the drug delivery device includes an osmotic engine internal to the device for creating fluid flow through the device.

Claims (13)

1. A drug delivery device, comprising:

a capsule for implantation into the body, said capsule comprising a first end, a second end and a fluid impermeable wall extending from the first end to the second end to define a reservoir; said capsule further comprising an exit port in communication with the reservoir and a nanopore membrane in communication with the exit port, wherein said device comprises a peptide or protein in the reservoir, said peptide or protein having molecular dimensions, and wherein said nanopore membrane has pores between 1-5 times the molecular dimensions of the peptide or protein to control release of the peptide or protein at a rate that approaches zero-order release for a period of about several weeks to about six months.

2. The drug delivery device of claim 1 , wherein said capsule further comprises a first end and a second end, and a first end cap and a second end cap positioned at the first and second ends.

3. The drug delivery device of claim 2 , wherein said capsule is tapered at the first and second ends.

4. The drug delivery device of claim 1 , wherein said capsule is substantially cylindrical in cross section.

5. The drug delivery device of claim 1 , wherein said capsule is manufactured from a material selected from the group consisting of titanium alloy, surgical grade stainless steel, and a polymeric material.

6. The drug delivery device of claim 1 , wherein said nanopore membrane comprises an array of parallel, annular channels.

7. The drug delivery device of claim 6 , wherein channels in the array of parallel, annular channels have a pore size of between 2-100 nm.

8. The drug delivery device of claim 1 , wherein said nanopore membrane comprises an array of parallel, rectangular channels.

9. The drug delivery device of claim 8 , wherein channels in the array of parallel, rectangular channels have a width of between 2-100 nm.

10. The drug delivery device of claim 1 , wherein the pepide or protein is dispersed within said reservoir as an aqueous solution or aqueous suspension.

11. The drug delivery device of claim 1 , wherein the peptide or protein is in dry form.

12. The drug delivery device of claim 1 , wherein the protein is growth hormone.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2016
From: MARTIN, FRANCIS J.; BOIARSKI, ANTHONY A.
To: IMEDD, INC.
Reel/Frame 039475/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2016
From: IMEDD, INC.
To: DELPOR, INC.
Reel/Frame 039475/0916 →
Continuity (6)
Continuation 13098067 · Apr 29, 2011
Continuation 11530729 · Sep 11, 2006
Continuation 10243787 · Sep 13, 2002
Provisional Application 60371290 · Apr 9, 2002
Provisional Application 60322160 · Sep 14, 2001
Related Publication 20140079754A1 · Mar 20, 2014